Evidence map›Paper›PMID 36991025›Full record

ArticleScientific reports2023

Retinal tissue and microvasculature loss in COVID-19 infection.

Fritz Gerald P Kalaw, Alexandra Warter, Melina Cavichini, Darren Knight, Alexandria Li, Daniel Deussen, Carlo Galang, Anna Heinke, Veronica Mendoza, Shyamanga Borooah and 4 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Fritz Gerald P Kalaw *Jacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Alexandra Warter *Jacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Melina CavichiniJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Darren KnightJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Alexandria LiJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Daniel DeussenJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Carlo GalangJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Anna HeinkeJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Veronica MendozaJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Shyamanga BorooahJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Sally L BaxterViterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Dirk-Uwe BartschJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
Lingyun ChengJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA.
William R FreemanJacobs Retina Center, 9415 Campus Point Drive, La Jolla, CA, 92037, USA. wrfreeman@health.ucsd.edu.
University of California, San Diego · USJacobs (United States) · USThe Retina Center · US

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Mechanistic-Based Non-Invasive Assessment of Retinal Damage in HAART EraR01EY016323 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BARTSCH, DIRK-UWE G · 2006 to 2020
$5.0M
Multi-modal Health Information Technology Innovations for Precision Management of GlaucomaDP5OD029610 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAXTER, SALLY LIU · 2020 to 2024
$2.1M
SCH: Multimodal Retina Image Alignment and ApplicationsR01EY033847 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AN, CHEOLHONG, BARTSCH, DIRK-UWE G · 2021 to 2024
$1.2M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY016323NEI NIH HHS R01 EY033847NIH HHS DP5 OD029610
6 · The paper itself

Abstract

This cross-sectional study aimed to investigate the hypothesis that permanent capillary damage may underlie the long-term COVID-19 sequela by quantifying the retinal vessel integrity. Participants were divided into three subgroups; Normal controls who had not been affected by COVID-19, mild COVID-19 cases who received out-patient care, and severe COVID-19 cases requiring intensive care unit (ICU) admission and respiratory support. Patients with systemic conditions that may affect the retinal vasculature before the diagnosis of COVID-19 infection were excluded. Participants underwent comprehensive ophthalmologic examination and retinal imaging obtained from Spectral-Domain Optical Coherence Tomography (SD-OCT), and vessel density using OCT Angiography. Sixty-one eyes from 31 individuals were studied. Retinal volume was significantly decreased in the outer 3 mm of the macula in the severe COVID-19 group (p = 0.02). Total retinal vessel density was significantly lower in the severe COVID-19 group compared to the normal and mild COVID-19 groups (p = 0.004 and 0.0057, respectively). The intermediate and deep capillary plexuses in the severe COVID-19 group were significantly lower compared to other groups (p < 0.05). Retinal tissue and microvascular loss may be a biomarker of COVID-19 severity. Further monitoring of the retina in COVID-19-recovered patients may help further understand the COVID-19 sequela.

Indexed as

COVID-19Cross-Sectional StudiesFluorescein AngiographyHumansMicrovesselsRetinaRetinal VesselsTomography, Optical Coherence

Identifiers

PMID36991025
PMCPMC10050819
OpenAlexW4361296306

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read7
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.